Related Experiment Video
Updated: Oct 13, 2025

Author Spotlight: A 3D Digital Model for the Diagnosis and Treatment of Pulmonary Nodules
Published on: May 19, 2023
Pulmonary nodules associated with JAK inhibitor therapy in rheumatoid arthritis: A case report
N Pannell1, D Joseph1, M M T M Ally1
1Department of Internal Medicine, Faculty of Health Sciences, University of Pretoria, South Africa.
Abstract:
Patients with rheumatoid arthritis (RA) may receive Janus kinase (JAK) inhibitors to achieve optimal control of their disease. We report a case of a patient who received a selective JAK1 inhibitor and subsequently developed multiple pulmonary nodules with cavitation. Biopsies confirmed the presence of cryptococcosis and the patient responded well to anti-fungal therapy.
Insights
Patients on Janus kinase (JAK) inhibitors for rheumatoid arthritis developed lung infections. A case study shows a JAK1 inhibitor led to cryptococcosis, which resolved with antifungal treatment.
Area of Science:
- Immunology
- Infectious Diseases
- Rheumatology
Background:
- Rheumatoid arthritis (RA) management often involves Janus kinase (JAK) inhibitors.
- Selective JAK1 inhibitors offer targeted therapy for RA.
- Understanding potential side effects is crucial for patient safety.
Observation:
- A patient with RA treated with a selective JAK1 inhibitor developed multiple pulmonary nodules.
- Imaging revealed cavitation within the nodules.
- These findings prompted further investigation.
Findings:
- Biopsies confirmed the presence of cryptococcosis, a fungal infection.
- The patient's condition was linked to JAK1 inhibitor therapy.
- Prompt diagnosis and treatment were initiated.
Implications:
- JAK inhibitors, including selective JAK1 agents, may increase susceptibility to opportunistic infections like cryptococcosis.
- Pulmonary nodules with cavitation in patients on JAK inhibitors warrant investigation for fungal infections.
- Effective antifungal therapy can successfully treat these infections, highlighting the importance of vigilant monitoring.
Related Concept Videos
The JAK-STAT Signaling Pathway
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

